{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:08:45Z","timestamp":1788930525670,"version":"build-2803163510"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>People living with HIV (PLWH) experience a growing burden of non-AIDS-defining malignancies in the era of effective antiretroviral therapy. Melanoma is an informative but understudied example because its progression and response to immune checkpoint inhibitors are shaped by host immunity and tumor antigen presentation. Yet PLWH have often been excluded from, or only conditionally included in, immunotherapy trials, leaving limited evidence to guide care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Scope<\/jats:title>\n                    <jats:p>Emerging clinical and translational studies suggest that melanoma in PLWH may differ from melanoma in HIV-negative patients not only in outcomes and treatment access, but also in antitumor immune organization. This Perspective proposes a spatial immuno-oncology framework in which chronic immune perturbation, impaired antigen presentation, exhausted T-cell states, and suppressive myeloid programs may converge in candidate tumor regions that are less visible to adaptive immunity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications<\/jats:title>\n                    <jats:p>We highlight the need for batch-balanced spatial profiling cohorts, validation of antigen-presentation pathways at the protein level, prospective immunotherapy studies on tissue samples, and trial eligibility criteria that safely include PLWH.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1921391","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:42:14Z","timestamp":1788928934000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Melanoma in people living with HIV: antigen-presentation loss, spatial immune escape, and inclusive immunotherapy trials"],"prefix":"10.3389","volume":"17","author":[{"given":"Alessio","family":"Giubellino","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Minnesota","place":["Minneapolis, MN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian P.","family":"Mansini","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Rush University Medical Center","place":["Chicago, IL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"B1","volume-title":"HIV Infection and Cancer Risk","year":"2025"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.5967","article-title":"Elevated cancer-specific mortality among HIV-infected patients in the United States","volume":"33","author":"Coghill","year":"2015","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"6637","DOI":"10.1038\/s41598-021-86081-w","article-title":"Exclusion of patients living with HIV from cancer immune checkpoint inhibitor trials","volume":"11","author":"Vora","year":"2021","journal-title":"Sci Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0095096","article-title":"Risk of melanoma in people with HIV\/AIDS in the pre- and post-HAART eras: A systematic review and meta-analysis of cohort studies","volume":"9","author":"Olsen","year":"2014","journal-title":"PLoS One"},{"key":"B5","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/QAI.0000000000001719","article-title":"Brief report: Cutaneous melanoma risk among people with HIV in the United States and Canada","volume":"78","author":"Yanik","year":"2018","journal-title":"J Acquired Immune Deficiency Syndromes"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.6.765","article-title":"Altered clinical course of malignant melanoma in HIV-positive patients","volume":"138","author":"Rodrigues","year":"2002","journal-title":"Arch Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-3148","article-title":"Population analysis and immunologic landscape of melanoma in people living with HIV","volume":"32","author":"Barger","year":"2026","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","author":"Sade-Feldman","year":"2017","journal-title":"Nat Commun"},{"key":"B10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"B11","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1158\/2159-8290.Cd-16-1223","article-title":"Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Cancer Discov"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.10.001","article-title":"Systemic effects of inflammation on health during chronic HIV infection","volume":"39","author":"Deeks","year":"2013","journal-title":"Immunity"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0472-9","article-title":"Multiplex digital spatial profiling of proteins and RNA in fixed tissue","volume":"38","author":"Merritt","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and microenvironment evolution during immunotherapy with nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"},{"key":"B16","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T cell states associated with response to checkpoint immunotherapy in melanoma","volume":"175","author":"Sade-Feldman","year":"2018","journal-title":"Cell"},{"key":"B17","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","article-title":"Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1\/anti-CTLA-4 combined therapy","volume":"35","author":"Gide","year":"2019","journal-title":"Cancer Cell"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"B19","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.cell.2018.09.006","article-title":"A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade","volume":"175","author":"Jerby-Arnon","year":"2018","journal-title":"Cell"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (Keynote-006): Post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02459","article-title":"Safety and activity of immune checkpoint inhibitors in people living with HIV and cancer: A real-world report from the Cancer Therapy Using Checkpoint Inhibitors in People Living with HIV-International (CATCH-IT) Consortium","volume":"41","author":"El Zarif","year":"2023","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.2244","article-title":"Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer\u2014a phase 1 study","volume":"5","author":"Uldrick","year":"2019","journal-title":"JAMA Oncol"},{"key":"B23","volume-title":"Cancer Clinical Trial Eligibility Criteria: Patients With HIV, Hepatitis B Virus, or Hepatitis C Virus Infections: Guidance for Industry","year":"2020"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10582","article-title":"Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1\/PD-L1 therapy","volume":"7","author":"Johnson","year":"2016","journal-title":"Nat Commun"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","article-title":"Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells","volume":"175","author":"Andr\u00e9","year":"2018","journal-title":"Cell"},{"key":"B28","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1158\/1078-0432.CCR-23-0475","article-title":"A phase II trial of the CD40 agonistic antibody sotigalimab (APX005M) in combination with nivolumab in subjects with metastatic melanoma with confirmed disease progression on anti-PD-1 therapy","volume":"30","author":"Weiss","year":"2024","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1921391\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:42:27Z","timestamp":1788928947000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1921391\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":28,"alternative-id":["10.3389\/fimmu.2026.1921391"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1921391","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"article-number":"1921391"}}